First Tracks Biotherapeutics (TRAXV) Stock Analysis

What First Tracks Biotherapeutics does

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology firm focused on advancing antibody therapies. These innovative treatments are designed to modulate immune system pathways that contribute to autoimmune and inflammatory diseases. The company, founded in 2025, has its headquarters in San Diego, California, and operates as a subsidiary of AnaptysBio, Inc.

Key metrics

ETFs linked to TRAXV

Broad-market and Healthcare sector ETFs an investor holding First Tracks Biotherapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TRAXV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for First Tracks Biotherapeutics?

First Tracks Biotherapeutics trades under the ticker TRAXV on NASDAQ.

Which exchange is TRAXV listed on?

TRAXV is listed on NASDAQ.

What sector does First Tracks Biotherapeutics operate in?

First Tracks Biotherapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TRAXV in a portfolio?

PortView shows TRAXV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.